Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Analytical Methods

Traylor, Matthew J., Bernhardt, Peter, Tangarone, Bruce S., Varghese, Johnson·2018·Biopharmaceutical Processing

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-08-100623-8.00047-5

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 62

  1. Kirschner, 2008, GLYCAM06: a generalizable biomolecular force field. Carbohydrates, J. Comput. Chem., 29, 622, 10.1002/jcc.20820 · DOI · Paper page
  2. Underwood, 2010, Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor, J. Biol. Chem., 285, 723, 10.1074/jbc.M109.033829 · DOI · Paper page
  3. Walsh, 2005, Protein posttranslational modifications: the chemistry of proteome diversifications, Angew. Chem. Int. Ed. Engl., 44, 7342, 10.1002/anie.200501023 · DOI · Paper page
  4. Patel, 2011, Stability considerations for biopharmaceuticals, Part 1: overview of protein and peptide degradation pathways, BioProcess Int., 9, 20
  5. Beck, 2013, Characterization of therapeutic antibodies and related products, Anal. Chem., 85, 715, 10.1021/ac3032355 · DOI · Paper page
  6. Bayry, 2007, Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action, Nat. Clin. Pract. Rheumatol., 3, 262, 10.1038/ncprheum0481 · DOI
  7. Haberger, 2014, Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes, MAbs, 6, 327, 10.4161/mabs.27876 · DOI · Paper page
  8. Abdiche, 2008, Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet, Anal. Biochem., 377, 209, 10.1016/j.ab.2008.03.035 · DOI · Paper page
  9. Mora, 2010, Application of the Gyrolab platform to ligand-binding assays: a user’s perspective, Bioanalysis, 2, 1711, 10.4155/bio.10.122 · doi:10.4155/bio.10.122
  10. Segel, 1975, vol. 957
  11. Bielefeld-Sevigny, 2009, AlphaLISA immunoassay platform- the “no-wash” high-throughput alternative to ELISA assay, Drug Dev. Technol., 7, 90, 10.1089/adt.2009.9996 · DOI
  12. Wang, 2009, Host cell proteins in biologics development: Identification, quantitation and risk assessment, Biotechnol. Bioeng., 103, 446, 10.1002/bit.22304 · DOI · Paper page
  13. Champion, 2005, Defining your product profile and maintaining control over it, part 2, BioProcess Int., 3, 52
  14. Bracewell, 2015, The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control, Biotechnol. Bioeng., 112, 1727, 10.1002/bit.25628 · DOI · Paper page
  15. Doneanu, 2012, Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry, MAbs, 4, 24, 10.4161/mabs.4.1.18748 · DOI · Paper page
  16. Schenauer, 2012, Identification and quantification of host cell protein impurities in biotherapeutics using mass spectrometry, Anal. Biochem., 428, 150, 10.1016/j.ab.2012.05.018 · DOI
  17. Zhang, 2013, Protein analysis by shotgun/bottom-up proteomics, Chem. Rev., 113, 2343, 10.1021/cr3003533 · DOI · Paper page
  18. Yang, 2010, A probabilistic model for risk assessment of residual host cell DNA in biological products, Vaccine, 28, 3308, 10.1016/j.vaccine.2010.02.099 · DOI
  19. Singer, 1997, Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation, Anal. Biochem., 249, 228, 10.1006/abio.1997.2177 · DOI · Paper page
  20. Rosenberg, 2006, Effects of protein aggregates: an immunologic perspective, AAPS J., 8, E501, 10.1208/aapsj080359 · DOI · Paper page
  21. Fekete, 2014, Theory and practice of size exclusion chromatography for the analysis of protein aggregates, J. Pharm. Biomed. Anal., 101, 161, 10.1016/j.jpba.2014.04.011 · DOI · Paper page
  22. Hong, 2012, A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates, J. Liq. Chromatogr. Relat. Technol., 35, 2923, 10.1080/10826076.2012.743724 · DOI · Paper page
  23. Ejima, 2005, Arginine as an effective additive in gel permeation chromatography, J. Chromatogr. A, 1094, 49, 10.1016/j.chroma.2005.07.086 · DOI
  24. Ricker, 1996, Fast, reproducible size-exclusion chromatography of biological macromolecules, J. Chromatogr. A, 743, 43, 10.1016/0021-9673(96)00283-X · DOI
  25. Patel, 2011, Stability considerations for biopharmaceuticals, Part 1: overview of protein and peptide degradation pathways, BioProcess Int., 9, 20
  26. Harris, 2001, Identification of multiple sources of charge heterogeneity in a recombinant antibody, J. Chromatogr. B Biomed. Sci. Appl., 752, 233, 10.1016/S0378-4347(00)00548-X · DOI · Paper page
  27. Meert, 2010, Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients, Anal. Chem., 82, 3510, 10.1021/ac902408r · DOI
  28. Sosic, 2008, Application of imaging capillary IEF for characterization and quantitative analysis of recombinant protein charge heterogeneity, Electrophoresis, 29, 4368, 10.1002/elps.200800157 · DOI
  29. Staub, 2011, Intact protein analysis in the biopharmaceutical field, J. Pharm. Biomed. Anal., 55, 810, 10.1016/j.jpba.2011.01.031 · DOI · Paper page
  30. Zhao, 2014, Applications of capillary electrophoresis in characterizing recombinant protein therapeutics, Electrophoresis, 35, 96, 10.1002/elps.201300372 · DOI
  31. Ambrogelly, 2012, Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide, MAbs, 4, 701, 10.4161/mabs.21614 · DOI
  32. Kotia, 2010, Analysis of monoclonal antibody product heterogeneity resulting from alternate cleavage sites of signal peptide, Anal. Biochem., 399, 190, 10.1016/j.ab.2010.01.008 · doi:10.1016/j.ab.2010.01.008
  33. Petersen, 2011, SignalP 4.0: discriminating signal peptides from transmembrane regions, Nat. Methods, 8, 785, 10.1038/nmeth.1701 · DOI · Paper page
  34. Dick, 2008, C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes, Biotechnol. Bioeng., 100, 1132, 10.1002/bit.21855 · DOI
  35. Harris, 2014, Amino acid misincorporation in recombinant biopharmaceutical products, Curr. Opin. Biotechnol., 30, 45, 10.1016/j.copbio.2014.05.003 · DOI
  36. Zhang, 2013, G/U and certain wobble position mismatches as possible main causes of amino acid misincorporations, Biochemistry, 52, 8165, 10.1021/bi401002c · DOI
  37. Traylor, 2016, Comprehensive discovery and quantitation of protein heterogeneity via LC-MS/MS peptide mapping for clone selection of a therapeutic protein, Anal. Chem., 88, 9309, 10.1021/acs.analchem.6b02895 · DOI
  38. Li, 2009, Pharmacological significance of glycosylation in therapeutic proteins, Curr. Opin. Biotechnol., 20, 678, 10.1016/j.copbio.2009.10.009 · DOI · Paper page
  39. Anumula, 2006, Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates, Anal. Biochem., 350, 1, 10.1016/j.ab.2005.09.037 · DOI · Paper page
  40. Beck, 2008, Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins, Curr. Pharm. Biotechnol., 9, 482, 10.2174/138920108786786411 · DOI · Paper page
  41. Harazono, 2011, A comparative study of monosaccharide composition analysis as a carbohydrate test for biopharmaceuticals, Biologicals, 39, 171, 10.1016/j.biologicals.2011.04.002 · doi:10.1016/j.biologicals.2011.04.002
  42. Stockert, 1995, The asialoglycoprotein receptor: relationships between structure, function, and expression, Physiol. Rev., 75, 591, 10.1152/physrev.1995.75.3.591 · DOI · Paper page
  43. Lis, 1998, Lectins: carbohydrate-specific proteins that mediate cellular recognition, Chem. Rev., 98, 637, 10.1021/cr940413g · DOI · Paper page
  44. Shah, 2014, LC-MS/MS peptide mapping with automated data processing for routine profiling of N-glycans in immunoglobulins, J. Am. Soc. Mass Spectrom., 25, 999, 10.1007/s13361-014-0858-3 · DOI
  45. Dong, 2016, A high-throughput, automated protein a purification platform with multi-attribute LC-MS analysis for advanced cell culture process monitoring, Anal. Chem., 88, 8673, 10.1021/acs.analchem.6b01956 · DOI
  46. Narhi, 2013, vol. 4
  47. Wei, 2014, Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications, Drug Discov. Today, 19, 95, 10.1016/j.drudis.2013.07.019 · DOI · Paper page
  48. Amezcua, 2013, Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy, J. Pharm. Sci., 102, 1724, 10.1002/jps.23531 · doi:10.1002/jps.23531
  49. Ghasriani, 2016, Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars, Nat. Biotechnol., 34, 139, 10.1038/nbt.3474 · doi:10.1038/nbt.3474
  50. Brooks, 2004, Appropriate glycosylation of recombinant proteins for human use, Mol. Biotechnol., 28, 241, 10.1385/MB:28:3:241 · DOI · Paper page
  51. Hamilton, 2007, Glycosylation engineering in yeast: the advent of fully humanized yeast, Curr. Opin. Biotechnol., 18, 387, 10.1016/j.copbio.2007.09.001 · DOI · Paper page
  52. Durocher, 2009, Expression systems for therapeutic glycoprotein production, Curr. Opin. Biotechnol., 20, 700, 10.1016/j.copbio.2009.10.008 · DOI · Paper page
  53. Chung, 2008, Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose, N. Engl. J. Med., 358, 1109, 10.1056/NEJMoa074943 · DOI · Paper page
  54. Borys, 2010, Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells, Biotechnol. Bioeng., 105, 1048, 10.1002/bit.22644 · DOI
  55. Noguchi, 1995, Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells, J. Biochem., 117, 59, 10.1093/oxfordjournals.jbchem.a124721 · DOI
  56. Padler-Karavani, 2008, Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease, Glycobiology, 18, 818, 10.1093/glycob/cwn072 · DOI · Paper page
  57. Tangvoranuntakul, 2003, Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid, Proc. Natl. Acad. Sci. U. S. A., 100, 12045, 10.1073/pnas.2131556100 · DOI · Paper page
  58. Jung, 2011, Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy, Curr. Opin. Biotechnol., 22, 858, 10.1016/j.copbio.2011.03.002 · DOI
  59. Chirino, 2004, Minimizing the immunogenicity of protein therapeutics, Drug Discov. Today, 9, 82, 10.1016/S1359-6446(03)02953-2 · DOI · Paper page
  60. Schellekens, 2002, Immunogenicity of therapeutic proteins: clinical implications and future prospects, Clin. Ther., 24, 1720, 10.1016/S0149-2918(02)80075-3 · DOI · Paper page
  61. Schellekens, 2003, Immunogenicity of therapeutic proteins, Nephrol. Dial. Transplant., 18, 1257, 10.1093/ndt/gfg164 · DOI
  62. Rathore, 2008, Case study and application of process analytical technology (PAT) towards bioprocessing: Use of on‐line high‐performance liquid chromatography (HPLC) for making real‐time pooling decisions for process chromatography, Biotechnol. Bioeng., 100, 306, 10.1002/bit.21759 · DOI

Cited by

See all 2

Metadata

Authors
Traylor, M. J., Bernhardt, P., Tangarone, B. S., & Varghese, J.
Venue
Biopharmaceutical Processing
Publisher
Elsevier
Published
2018
Pages
1001-1049
Cited by
1
References
3
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analytical Methods. https://app.cochat.ai/papers/10.1016/b978-0-08-100623-8.00047-5
The paper
Traylor, M. J., Bernhardt, P., Tangarone, B. S., & Varghese, J. (2018). Analytical Methods. Biopharmaceutical Processing. https://doi.org/10.1016/b978-0-08-100623-8.00047-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.